Express News | HC Wainwright & Co. Reiterates Buy on Sangamo Therapeutics, Maintains $5 Price Target
Why General Dynamics Shares Are Trading Lower? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
Dow Tumbles 300 Points; Tesla Shares Plunge After Q2 Results
Sangamo Stock Spikes As Pfizer Partnership Meets Goal In Late-Stage Study
Express News | Sangamo Therapeutics Shares Resume Trade
Express News | Sangamo Therapeutics Shares up 69.5% to 68 Cents After Pfizer's Gene Therapy Cuts Bleeding Rate in Late-Stage Trial
Express News | Sangamo Therapeutics Shares Halted On Circuit Breaker To The Downside, Stock Now Up 69.5%
Express News | Sangamo Therapeutics Shares Are Trading Higher After Licensing Partner Pfizer's Phase 3 AFFINE Trial Evaluating Giroctocogene Fitelparvovec Met Its Primary Endpoint
Express News | Sangamo Therapeutics Announces Pfizer's Phase 3 Trial Of Giroctocogene Fitelparvovec Meets Primary And Key Secondary Objectives; Eligible For Up To $220M In Milestone Payments And 14%-20% Royalties If Approved And Commercialized
Pfizer's (PFE.US) gene therapy for type A hemophilia has achieved positive results in key trials.
Pfizer's gene therapy for treating hemophilia A achieved its goal in a critical late-stage trial, paving the way for the company to enter this challenging market.
Pfizer/ Sangamo Gene Therapy for Hemophilia A Succeeds in Late-stage Trial
Express News | Sangamo Therapeutics Reports on Pfizer’s Announcement of Positive Topline Results From Phase 3 Trial of Hemophilia a Gene Therapy Candidate
Express News | Pfizer Announces Positive Topline Results From Phase 3 Study of Hemophilia a Gene Therapy Candidate
Express News | Pfizer: Analyses of Full Phase 3 Dataset From Affine Study Ongoing
Express News | Pfizer: In Affine Study, Giroctocogene Fitelparvovec Was Generally Well Tolerated
Express News | Pfizer: Affine Study Meets Primary and Key Secondary Objectives
The Market Doesn't Like What It Sees From Sangamo Therapeutics, Inc.'s (NASDAQ:SGMO) Revenues Yet As Shares Tumble 30%
Nektar, Verastem Among Healthcare Additions in Russell Microcap; Assertio, Sangamo Removed
Russell 3000: Inovio, Ocugen Among Healthcare Additions; Assertio, Ginkgo Bioworks Among Deletions
Critical Insights From Sangamo Therapeutics Analyst Ratings: What You Need To Know